New split-dose chemo aims to help elderly lymphoma patients
NCT ID NCT03943901
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a modified schedule of standard chemotherapy (R-CHOP) for people aged 75 and older with diffuse large B-cell lymphoma, a type of blood cancer. The goal is to see if splitting the doses makes treatment easier to tolerate while still being effective. Twenty-seven participants will receive the split-dose regimen and be followed for about 2.5 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) with pegfilgrastim
- What this could lead to
- If successful, this split-dose schedule could offer a better-tolerated treatment option for older adults with DLBCL, potentially improving response rates and quality of life.
- What could go wrong
- This is a small, early-phase (phase II) study with only 27 participants, so results may not apply broadly. Chemotherapy side effects remain a risk, and the split-dose approach may not improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53705, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Could sitting up make radiation therapy more comfortable?
- Can an immune booster outsmart brain lymphoma?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?